COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03090737
Recruitment Status : Active, not recruiting
First Posted : March 27, 2017
Last Update Posted : September 16, 2020
Ono Pharmaceutical Co. Ltd
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Biological: Nivolumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)
Actual Study Start Date : May 26, 2017
Estimated Primary Completion Date : March 7, 2021
Estimated Study Completion Date : November 28, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Nivolumab
Specified Dose on Specified Days
Biological: Nivolumab
Specified Dose on Specified Days
Other Names:
  • BMS-936558
  • Opdivo

Primary Outcome Measures :
  1. Incidence of high grade (Grades 3-4 and Grade 5) treatment-related adverse events [ Time Frame: Up to 5 years ]

Secondary Outcome Measures :
  1. Progression-free Survival (PFS) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) [ Time Frame: Up to 5 years ]
  2. Objective Response Rate (ORR) as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) [ Time Frame: Up to 5 years ]
  3. Overall Survival (OS) [ Time Frame: Up to 5 years ]
  4. Duration of Response (DOR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) [ Time Frame: Up to 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

  • Non small cell lung cancer (Squamous or non-squamous)
  • At least one prior anti-cancer therapy that did not work
  • ECOG Performance Scale 0-1

Exclusion Criteria:

  • Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
  • Active, known or suspected autoimmune disease or infection
  • Prior immuno-oncology therapy
  • Corticosteroids within 2 weeks of study drug administration

Other protocol defined inclusion/exclusion criteria could apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03090737

Layout table for location information
United States, Alabama
Alabama Oncology
Birmingham, Alabama, United States, 35205
United States, California
Los Angeles Hematology Oncology Medical Group
Los Angeles, California, United States, 90017
United States, Montana
St Vincent Frontier Cancer Center
Billings, Montana, United States, 59102
United States, New York
Broome Oncology
Johnson City, New York, United States, 13790
United States, Pennsylvania
Guthrie Medical Group, Pc
Sayre, Pennsylvania, United States, 18840
Canada, Ontario
Kingston Health Sciences Centre Kingston General Hospital Site
Kingston, Ontario, Canada, K7L 2V7
Lakeridge Health
Oshawa, Ontario, Canada, L1G 2B9
Local Institution
Toronto, Ontario, Canada, M5G 2M9
Local Institution
Nagoya, Aichi, Japan, 4648681
Local Institution
Chuo-ku, Osaka, Japan, 5418567
Local Institution
Chuo-ku, Tokyo, Japan, 1040045
Local Institution
Koto, Tokyo, Japan, 135-8550
Local Institution
Bucharest, Romania, 020122
Local Institution
Craiova, Romania, 200347
South Africa
Local Institution
Port Elizabeth, Eastern CAPE, South Africa, 6045
Local Institution
Parktown, Johannesburg, Gauteng, South Africa, 2193
Local Institution
George, Western CAPE, South Africa, 6530
Sponsors and Collaborators
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT03090737    
Other Study ID Numbers: CA209-907
2016-003731-37 ( EudraCT Number )
First Posted: March 27, 2017    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Immunological
Antineoplastic Agents